麻豆传媒

Mouhamed Alsaqati is a neuropharmacology lecturer in the School of Pharmacy at the 麻豆传媒, 麻豆传媒 upon Tyne, UK. He serves as the Stage 3 Lead for the MPharm programme and he is a Senior Fellow of the Higher Education Academy.

He obtained his PhD in Physiology and Pharmacology from the University of Nottingham. He has been working as a senior research associate in the Neuroscience and Mental Health Innovation Institute at Cardiff University in academic partnerships with Takeda Pharmaceutical Company.

Alsaqati Reserach Group: https://blogs.ncl.ac.uk/mouhamedalsaqati/

I am interested in learning the molecular mechanism underlying the in the pathogenesis of various brain disorders including neuropsychiatric, neurodegenerative and pain disorders. I use patient derived pluripotent stem cells and differentiate them into neural linage cells. Then the functional phenotype of these cells can be tested using a number of functional assays including patch-clamping and the multi-electrode arrays (MEAs), which is a platform that tests the neuronal excitability, synchronicity and connectivity. I use the combination of genetics, cellular and electrophysiological components to understand the mechanism underlying the neuropsychiatric disorders. Following identifying the molecular mechanism of the disorders, I employ my pharmacological and genetic (CRISPR) tools to rescue their aberrant phenotypes.

My research can serve as a fundamental translational platform for patients with neurological disorders as drugs used to rescue the atypical functional phenotype in human neuronal cellular models can be applied in human or animal brains of relevant diseases to correct their aberrant behaviours.

PhD supervision:

·    Primary Supervisor for a student studying pain in Parkinson’s disease using iPSC-derived sensory neurons.

·   Primary Supervisor for a student investigating the phenotypes of GABAergic neurons in Parkinson’s disease patients.

. Primary Supervisor for a student investigating the phenotypic effects of TSC mutations in chronic pain.

·     Secondary Supervisor for a student examining the role of TANC2 in autism using iPSC-derived neurons.

·    External Secondary Supervisor for a student studying perturbations in the process of endocytosis in FADS2 mutant cells, in collaboration with Cardiff University.

I am contributing to the following modules:

Mpharm Course

Stage 1 (PHA1006)

• Biochemistry: Carbohydrate, protein and lipids
• Structure of Cellular Membranes
• Cellular Replication: DNA, RNA and Protein Synthesis
• Ion Channels and Cellular Homeostasis
• Extracellular Receptor Cellular Signalling Pathways 1
• Extracellular Receptor Cellular Signalling Pathways 2
• Nuclear Hormone Receptor Signalling Pathways
• Immune System
• Respiratory System
• Normal Pulmonary Physiology
• Nervous System – CNS, PNS
• Renal System Function and Physiology
• Paracetamol pharmacology
• Virtual Ileum Practical

Stage 2 (PHA2006)

• Pathophysiology and pharmacology of asthma and COPD
• Physiology and Pharmacology of Inflammation & Autoimmunity
• Large intestine, Constipation, Diarrhoea and Lactose Intolerance
• Drug Metabolism and Pharmacokinetics
• Respiratory Tract Infections

Stage 3 (PHA3006)

MPharm stage 3 module lead

• Anxiety and insomnia: pathophysiology and pharmacology
• Parkinson’s pathophysiology and pharmacology
• Parkinson’s pharmaceutical care
• Applied pharmacology workshop
• Pathophysiology of RA
• Diabetes pathogenies

Stage 4 (PHA4006)

• The immune system
• Vaccines

Dentistry (DEN1107)

• Peripheral Nerves and Peripheral Sensory receptors
• Pain mechanisms

MRes Neuroscience (MMB8010)

• Manipulating neuronal function-pharmacolog

Bachelor of Medicine, Bachelor of Surgery (MB BS, (A100) (A101))

• Parkinson’s pathophysiology and pharmacology and clinical care

• Articles

  • Merza, J, Alsaqati, M, Wills, C, Waddell, PG, Ashton, M. The Synthesis and Biological Activity of Series of New Polyfunctional Pyrroles with the Potential to Modulate Neuronal Viabilit. Cell Biochemistry and Biophysics 2026, https://link.springer.com/article/10.1007/s12013-026-02090-4. In Preparation.
  • Alsaqati M, Haddon JE, Hall J, Harwood AJ, Wilkinson LS. . Neuropharmacology 2026, 292, 110952.
  • Elmorsy EM, Al-Ghafari AB, Al Doghaither HA, Elghareeb MM, Alsaqati M. . Journal of Molecular Neuroscience 2025, 75(2), 46.
  • Alsaqati M, Thomas RS, Kidd EJ. . Aging Brain 2023, 4, 100084.
  • Dec K, Alsaqati M, Morgan M, Wood J, Hall J, Harwood AJ. . Frontiers in Cell and Developmental Biology, Stem Cell Research 2023, 11, 166808.
  • Chapman G, Alsaqati M, Lunn S, Singh T, Linden SC, Linden DEJ, van den Bree MBM, Ziller M, Owen MJ, Hall J, Harwood AJ, Syed YA. . Molecular Psychiatry 2022, 27, 819-830.
  • Alsaqati M, Davis BA, Wood J, Jones MM, Jones L, Westwood A, Petter O, Isles AR, Linden D, Van den Bree M, Owen M, Hall J, Harwood AJ. . Translational Psychiatry 2022, 12(1), 438.
  • Alsaqati M, Heine VM, Harwood AJ. . Molecular Autism 2020, 11, 80.
  • Susruta M, Alsaqati M. Glycyrrhizin blocks the detrimental effects of HMGB1 on cortical neurogenesis after traumatic neuronal injury. Brain Sciences 2020, 10, 760.
  • Nadadhur AG, Alsaqati M. . Stem Cell Reports 2019, 12(1), 42-56.
  • Alsaqati M, Kidd E. . Journals of Gerontology: Series A 2017, 73(3), 289-298.
  • Thomas R, Alsaqati M. Alterations in endocytic protein expression with increasing age in the transgenic APP695 V717I London mouse model of amyloid pathology - implications for Alzheimer's disease. NeuroReport 2017, 28, 963-968.
  • Alsaqati M, Latif ML, Chan SLF, Ralevic V. . British Journal of Pharmacology 2014, 171, 701-713.
  • Alsaqati M, Chan SLF, Ralevic V. . Purinergic Signalling 2014, 10, 241-249.

• Authored Book

  • Alsaqati M. . Nottingham: University of Nottingham, 2014.